CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA

CASI Pharmaceuticals ( (CASI) ) just unveiled an update.

CASI Pharmaceuticals announced that the FDA has placed a clinical hold on its CID-103, an anti-CD38 antibody for the treatment of Antibody Mediated Rejection (AMR) in kidney transplant patients. Despite this setback, the company continues to progress with its phase 1-2 study of CID-103 for chronic Immune Thrombocytopenia (ITP), with patient recruitment expected to begin in the first quarter of 2025.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a company based in Beijing, China, and incorporated in the Cayman Islands. The company operates in the pharmaceutical industry, with a focus on developing innovative therapies, particularly in the field of oncology and other unmet medical needs.

YTD Price Performance: -60.61%

Average Trading Volume: 42,621

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $37.79M

For an in-depth examination of CASI stock, go to TipRanks’ Stock Analysis page.